This inventor holds 1 USPTO granted patent. Top assignee: Teva Pharmaceutical Industries Limited. Active years: 1991.
Company Filing History:
Years Active: 1991
Title: Shmuel Edelstein: Innovator in Renal Treatment
Introduction
Shmuel Edelstein is a notable inventor based in Rehovot, Israel. He has made significant contributions to the field of medicine, particularly in the treatment of renal conditions. His innovative approach has led to the development of a unique patent that addresses a critical health issue.
Latest Patents
Edelstein holds a patent for a method and composition aimed at improving the treatment of human renal osteodystrophy. This patent, titled "Combination of cholecalciferol derivatives for the treatment of renal," involves the administration of 6-40 mcg/d of 24,25(OH)₂D₃ in combination with 1-alpha(OH)D₃ or 1,25(OH)₂D₃ or DHT₂. The goal is to maintain serum calcium concentrations at 10-11 mg/dl and phosphate concentrations at 5.5-6.0 mg/dl, ensuring that the numerical multiplication product of calcium and phosphate does not exceed 60-65.
Career Highlights
Edelstein is associated with Teva Pharmaceutical Industries Limited, a leading global pharmaceutical company. His work at Teva has allowed him to focus on innovative solutions for complex medical challenges. His dedication to research and development has positioned him as a key figure in the pharmaceutical industry.
Collaborations
Throughout his career, Edelstein has collaborated with esteemed colleagues, including Benjamin Shalita and Zeev Mazor. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Shmuel Edelstein's contributions to renal treatment through his patented methods highlight his commitment to advancing medical science. His work continues to impact the lives of patients suffering from renal osteodystrophy, showcasing the importance of innovation in healthcare.